<dd id="auefl"><noscript id="auefl"></noscript></dd>

          <button id="auefl"></button>
          <rp id="auefl"></rp>
          <button id="auefl"></button><tbody id="auefl"><pre id="auefl"></pre></tbody><button id="auefl"></button>

              <tbody id="auefl"></tbody>
              • 2021
              • 2020
              • 2019
              • 2018
              • 2017
              • 2016
              2021-01

              In January, the first patient was enrolled in Phase I clinical trial for MIL95 (CD47 antibody);

              2021-04

              In April, the first patient was enrolled in Phase I clinical trial for MIL93 (Claudin 18.2 antibody);

              2021-05

              In May, we filed IND application to NMPA for MIL97 (CD40 antibody), and we obtained IND approval from NMPA for MIL62 (Third-generation CD20 antibody) to treat PMN

              2021-06

              In June, the first patient was enrolled in Phase III clinical trial for MIL62 for the treatment of relapsed/refractory FL
              We completed investments undertaken by, among others, Tigermed and WuXi Biologics.

              2020-05

              In May, we completed the Phase III trial for MIL60 (Bevacizumab biosimilar) and filed the NDA application in June;
              we obtained IND approval from NMPA for MIL95 (CD47 antibody);

              2020-07

              In July, the first patient was enrolled in Phase I/IIa clinical trial for the combination of MIL62 (Third-generation CD20 antibody) with BTK inhibitor;

              2020-08

              In August, the first patient was enrolled in Phase I clinical trial for MBS301 (HER2/HER2 bispecific antibody);

              2020-10

              In October, we obtained IND approval from NMPA for MIL93 (Claudin 18.2 antibody);

              2020-12

              In December, we obtained IND approval from NMPA for MIL62 to treat LN;
              We completed investments undertaken by, among others, CICC Capital, CITIC Investment, LYZZ Capital, SDIC and Lake Bleu Capital.

              2019-03

              In March, we signed a collaboration agreement with InnoCare (stock code: 09969.HK) regarding the combination of MIL62 (Third-generation CD20 antibody) with BTK inhibitor, and obtained IND approval from NMPA for the combination therapy in August;

              2019-04

              In April, we obtained IND approval from NMPA for MIL86 (PCSK9 antibody);

              2019-09

              In September, we filed a PCT patent application for MIL93 (Claudin 18.2 antibody);

              2019-10

              In October, we filed a PCT patent application for MIL97 (CD40 antibody);

              2019-11

              In November, the first patient was enrolled in Phase II clinical trial for MIL62 for the treatment of relapsed/refractory FL;
              We completed investments undertaken by, among others, CASVC and E-Town International Investment.

              2018-01

              In January, we signed a collaboration agreement with Keymed (stock code: 02162.HK) regarding the development of MIL95 (CD47 antibody).

              2017-03

              In March, we signed a collaboration agreement with Betta (stock code: 300558.SZ) to develop, manufacture and commercialize MIL60 (Bevacizumab biosimilar), and the Phase III clinical trial for MIL60 was initiated in August;

              2017-07

              In July, we filed a PCT patent application for MBS301 (HER2/HER2 bispecific antibody);
              In August, we filed a PCT patent application for MIL62 (Third-generation CD20 antibody).

              2016-10

              In October, we obtained IND approval from NMPA for our core product MIL62 (Third-generation CD20 antibody) for the treatment of relapsed/refractory B-cell lymphoma;
              We completed investments undertaken by, among others, GIG and Harvest Investments.

              樱花动漫APP正版下载,在卫生间被教官做好爽H,同桌上课吃我的小兔兔作文,二本道日本一区免费